PARP Inhibitor Re‑sensitizes Adriamycin Resistant Leukemia Cells Through DNA Damage and Apoptosis

Molecular Medicine Reports - Greece
doi 10.3892/mmr.2018.9628
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

PARP Inhibition Sensitizes P53-Deficient Breast Cancer Cells to Doxorubicin-Induced Apoptosis

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2005English

Brca2Deficiency Sensitizes Cells to PARP Inhibition

Cancer Research
Cancer ResearchOncology
2006English

The NEDD8-activating Enzyme Inhibitor MLN4924 Induces DNA Damage in Ph+ Leukemia and Sensitizes for ABL Kinase Inhibitors

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2019English

mTORC1/2 Inhibition Re-Sensitizes Platinum-Resistant Ovarian Cancer by Disrupting Selective Translation of DNA Damage and Survival mRNAs

Oncotarget
Oncology
2018English

PARP Inhibitor Veliparib and HDAC Inhibitor SAHA Synergistically Co-Target the UHRF1/BRCA1 DNA Damage Repair Complex in Prostate Cancer Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

EZH2 Inhibition Re-Sensitizes Multidrug Resistant B-Cell Lymphomas to Etoposide Mediated Apoptosis

Oncoscience
Cancer ResearchOncology
2016English

Loss of Urokinase Receptor Sensitizes Cells to DNA Damage and Delays DNA Repair

PLoS ONE
Multidisciplinary
2014English

Regulation of DNA Damage Response and Cell Cycle in Radiation-Resistant HL60 Myeloid Leukemia Cells

Oncology Reports
MedicineCancer ResearchOncology
2012English

Zoledronic Acid Overcomes Adriamycin Resistance in Acute Myeloid Leukemia Cells by Promoting Apoptosis

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy